The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

While the ABB FIA Formula E World Championship is just 10 full seasons old, the on-track technology is ever-evolving and has undergone revolutionary changes in that 10-year spell. We've come a long ...

Abstract: A simple and efficient recursive formula to calculate the S-parameters of large, finite periodic structures is introduced. The technique utilizes measured or computed S matrices of ...

Scuderia Ferrari Driver Academy driver is pleased to announce that Rafael Câmara will make the step up to Formula 2 in 2026 with Invicta Racing, after a remarkable season that saw him crowned 2025 FIA ...

These are direct-prediction models trained from scratch on small, heavily augmented datasets—not few-shot prompting. ARC remains the canonical target; broader leaderboard context and rules (e.g., ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...